HK1093223A1 - Methods and compositions for the correlation of single nucleotide polymorphisms in the vitamin epoxide reductase gene and warfarin dosage - Google Patents

Methods and compositions for the correlation of single nucleotide polymorphisms in the vitamin epoxide reductase gene and warfarin dosage

Info

Publication number
HK1093223A1
HK1093223A1 HK06114003.0A HK06114003A HK1093223A1 HK 1093223 A1 HK1093223 A1 HK 1093223A1 HK 06114003 A HK06114003 A HK 06114003A HK 1093223 A1 HK1093223 A1 HK 1093223A1
Authority
HK
Hong Kong
Prior art keywords
single nucleotide
vitamin
correlation
compositions
methods
Prior art date
Application number
HK06114003.0A
Other languages
English (en)
Chinese (zh)
Inventor
Darrel W Stafford
Tao Li
Original Assignee
Univ North Carolina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34393028&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1093223(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ North Carolina filed Critical Univ North Carolina
Publication of HK1093223A1 publication Critical patent/HK1093223A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
HK06114003.0A 2003-09-23 2006-12-20 Methods and compositions for the correlation of single nucleotide polymorphisms in the vitamin epoxide reductase gene and warfarin dosage HK1093223A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50552703P 2003-09-23 2003-09-23
PCT/US2004/031481 WO2005030039A2 (en) 2003-09-23 2004-09-23 Methods and compositions for the correlation of single nucleotide polymorphisms in the vitamin k epoxide reductase gene and warfarin dosage

Publications (1)

Publication Number Publication Date
HK1093223A1 true HK1093223A1 (en) 2007-02-23

Family

ID=34393028

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06114003.0A HK1093223A1 (en) 2003-09-23 2006-12-20 Methods and compositions for the correlation of single nucleotide polymorphisms in the vitamin epoxide reductase gene and warfarin dosage

Country Status (13)

Country Link
US (6) US7687233B2 (xx)
EP (4) EP2380985B1 (xx)
JP (4) JP2007506433A (xx)
AT (1) ATE455174T1 (xx)
AU (2) AU2004275828B2 (xx)
CA (1) CA2539434C (xx)
DE (1) DE602004025157D1 (xx)
DK (2) DK1842920T4 (xx)
ES (2) ES2453895T3 (xx)
HK (1) HK1093223A1 (xx)
PL (1) PL1842920T5 (xx)
PT (1) PT2380985E (xx)
WO (1) WO2005030039A2 (xx)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2380985B1 (en) 2003-09-23 2014-01-01 University of North Carolina at Chapel Hill Cells expressing vitamin K epoxide reductase and use thereof
DE602004026897D1 (de) * 2003-10-14 2010-06-10 Baxter Healthcare Sa Vkorc1 (vitamin k epoxide recycling polypeptide), ein therapeutisches ziel für coumarin und deren derivate
GB0324044D0 (en) 2003-10-14 2003-11-19 Astrazeneca Ab Protein
WO2006012902A2 (en) * 2004-08-02 2006-02-09 Novozymes A/S Creation of diversity in polypeptides
US7445896B2 (en) * 2004-10-18 2008-11-04 University Of Washington Methods and compositions for detecting VKORC1 single nucleotide polymorphisms
CA2583904C (en) * 2004-10-18 2018-01-09 University Of Washington Methods and compositions for predicting drug responses
MX2007007568A (es) * 2004-12-21 2008-03-11 Academia Sinica Variantes geneticas de vkorci que predicen la sensibilidad a la warfarina.
CN103396998A (zh) * 2005-02-28 2013-11-20 巴克斯特国际公司 重组共表达维生素k环氧化物还原酶亚基1以提高依赖维生素k的蛋白质表达
AU2005329450A1 (en) * 2005-03-15 2006-09-28 University Of North Carolina At Chapel Hill Methods and compositions for producing active Vitamin K-dependent proteins
US7989193B2 (en) * 2005-04-13 2011-08-02 Medimmune Limited Compositions and methods for producing gamma-carboxylated proteins
US8500720B2 (en) * 2005-05-09 2013-08-06 Medtronic, Inc Method and apparatus for treatment of cardiac disorders
EP1969127B8 (en) * 2005-12-21 2017-12-13 Aptevo BioTherapeutics LLC Method of producing biologically active vitamin k dependent proteins by recombinant methods
US20070298426A1 (en) * 2006-06-02 2007-12-27 Academia Sinica Warfarin dosage prediction
US8206967B2 (en) 2007-07-06 2012-06-26 Medimmune Limited Method for production of recombinant human thrombin
CN102046205A (zh) 2008-04-24 2011-05-04 凯尔特药物Peg有限公司 具有延长的半衰期的因子ix缀合物
US20110243958A1 (en) * 2008-10-15 2011-10-06 President And Fellows Of Harvard College Antimicrobial agents that target bacterial vkor
ES2475718T3 (es) 2009-07-10 2014-07-11 Csl Limited Método para incrementar el rendimiento de la expresión de proteínas dependientes de vitamina K
EP2655607A4 (en) 2010-12-21 2014-05-14 Univ North Carolina METHOD AND COMPOSITIONS FOR PRODUCING ACTIVE VITAMIN K-DEPENDENT PROTEINS
JP2012139232A (ja) * 2012-03-15 2012-07-26 Univ Of North Carolina At Chapel Hill 活性ビタミンｋ依存性タンパク質を生産するための方法及び組成物
JP2014221048A (ja) * 2014-06-16 2014-11-27 ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 活性ビタミンｋ依存性タンパク質を生産するための方法及び組成物
BR102015012334A2 (pt) 2015-05-27 2016-11-29 Fundação Hemoct De Ribeirão Preto Fundherp processo de produção do fator vii de coagulação sanguínea e fator vii de coagulação sanguínea
EP4252629A3 (en) 2016-12-07 2023-12-27 Biora Therapeutics, Inc. Gastrointestinal tract detection methods, devices and systems
EP3554541B1 (en) 2016-12-14 2023-06-07 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
EP3883634A1 (en) 2018-11-19 2021-09-29 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
EP4309722A2 (en) 2019-12-13 2024-01-24 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IE58011B1 (en) 1983-05-27 1993-06-16 Texas A & M Univ Sys Method for producing a recombinant baculovirus expression vector
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
ATE74164T1 (de) 1985-04-22 1992-04-15 Genetics Inst Herstellung mit hoher leistung des aktivfaktors ix.
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
JPH01502080A (ja) 1986-11-17 1989-07-27 ニュー・イングランド・メディカル・センター 組み換えビタミンｋ依存性蛋白質のガンマカルボキシル化の増強
WO1989012685A1 (en) 1987-05-18 1989-12-28 Integrated Genetics, Inc. Improved protein c molecules and method for making and activating same
AU634186B2 (en) 1988-11-11 1993-02-18 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
WO1991001372A1 (en) 1989-07-17 1991-02-07 New England Medical Center Hospitals, Inc. VITAMIN K-DEPENDENT η-CARBOXYLASE
WO1992001795A1 (en) 1990-07-23 1992-02-06 Zymogenetics, Inc. Gamma-carboxylase and methods of use
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5169784A (en) 1990-09-17 1992-12-08 The Texas A & M University System Baculovirus dual promoter expression vector
CA2096418C (en) 1990-11-26 2001-11-20 Philip J. Barr Expression of pace in host cells and methods of use thereof
US5965789A (en) 1991-01-11 1999-10-12 American Red Cross Engineering protein posttranslational modification by PACE/furin in transgenic non-human mammals
US5268275A (en) 1991-05-08 1993-12-07 The University Of North Carolina At Chapel Hill Vitamin K-dependent carboxylase
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
US5698765A (en) 1991-12-02 1997-12-16 The Ontario Cancer Institute Mouse having a disrupted CD4 gene
WO1993018144A1 (en) 1992-03-05 1993-09-16 The Trustees Of Columbia University Of The City Of New York Recombination activating gene deficient animal
US5625122A (en) 1992-04-24 1997-04-29 The Ontario Cancer Institute Mouse having a disrupted lck gene
JP3741447B2 (ja) 1992-10-23 2006-02-01 中外製薬株式会社 エンドセリン−１遺伝子の機能が欠損したマウス
CA2153387A1 (en) 1993-01-07 1994-07-21 Hubert Koester Dna sequencing by mass spectrometry
US5605798A (en) 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
AU2860295A (en) 1994-06-16 1996-01-05 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Defects in drug metabolism
ZA965853B (en) 1995-07-13 1998-01-12 Du Pont Merck Pharma Asymmetric synthesis of r and s warfarin and its analogs.
DE19625049A1 (de) 1996-06-22 1998-01-02 Inst Pflanzengenetik & Kultur Transgenes, nicht-menschliches Säugetier, das ein zusätzliches DNA-Reparaturgen enthält
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
US6531298B2 (en) 1997-07-21 2003-03-11 The University Of North Carolina At Chapel Hill Factor IX antihemophilic factor with increased clotting activity
WO1999033983A1 (en) 1997-12-24 1999-07-08 Immunex Corporation V201 dna and polypeptides
US5896337A (en) 1998-02-23 1999-04-20 Micron Technology, Inc. Circuits and methods for multi-level data through a single input/ouput pin
CA2332307A1 (en) * 1998-07-10 2000-01-20 Incyte Pharmaceuticals, Inc. Human transport protein homologs
JP2002530485A (ja) * 1998-11-18 2002-09-17 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 蛍光材料
WO2000054787A1 (en) 1999-03-16 2000-09-21 The Children's Hospital Of Philadelphia Enhanced gamma-carboxylation of recombinant vitamin k-dependent clotting factors
US6453244B1 (en) * 2000-02-10 2002-09-17 Stanford University Detection of polymorphisms by denaturing high-performance liquid chromatography
US6492115B1 (en) 2000-06-02 2002-12-10 Dna Sciences Laboratories, Inc. Genetic typing of the human cytochrome P450 2A6 gene and related materials and methods
DE60141908D1 (de) 2000-10-02 2010-06-02 Novo Nordisk Healthcare Ag Glykoformen von faktor vii
US7125841B2 (en) 2000-11-14 2006-10-24 The University Of Texas Systems Mutant human factor IX with an increased resistance to inhibition by heparin
CA2441417A1 (en) * 2001-03-21 2002-11-14 Human Genome Sciences, Inc. Human secreted proteins
EP2380985B1 (en) 2003-09-23 2014-01-01 University of North Carolina at Chapel Hill Cells expressing vitamin K epoxide reductase and use thereof
GB0324044D0 (en) 2003-10-14 2003-11-19 Astrazeneca Ab Protein
DE602004026897D1 (de) 2003-10-14 2010-06-10 Baxter Healthcare Sa Vkorc1 (vitamin k epoxide recycling polypeptide), ein therapeutisches ziel für coumarin und deren derivate
US7445896B2 (en) 2004-10-18 2008-11-04 University Of Washington Methods and compositions for detecting VKORC1 single nucleotide polymorphisms
CA2583904C (en) 2004-10-18 2018-01-09 University Of Washington Methods and compositions for predicting drug responses
MX2007007568A (es) 2004-12-21 2008-03-11 Academia Sinica Variantes geneticas de vkorci que predicen la sensibilidad a la warfarina.
EP1831363A1 (en) 2004-12-21 2007-09-12 Novo Nordisk Health Care AG Expression of gamma-carboxylated polypeptides in gamma-carboxylation deficient host systems
CN103396998A (zh) 2005-02-28 2013-11-20 巴克斯特国际公司 重组共表达维生素k环氧化物还原酶亚基1以提高依赖维生素k的蛋白质表达
AU2005329450A1 (en) * 2005-03-15 2006-09-28 University Of North Carolina At Chapel Hill Methods and compositions for producing active Vitamin K-dependent proteins
US7989193B2 (en) 2005-04-13 2011-08-02 Medimmune Limited Compositions and methods for producing gamma-carboxylated proteins
WO2007065173A2 (en) 2005-12-02 2007-06-07 Wake Forest University Health Sciences Compositions and methods for increasing production of recombinant gamma-carboxylated proteins
EP1969127B8 (en) 2005-12-21 2017-12-13 Aptevo BioTherapeutics LLC Method of producing biologically active vitamin k dependent proteins by recombinant methods
US20070298426A1 (en) * 2006-06-02 2007-12-27 Academia Sinica Warfarin dosage prediction
JP2009005240A (ja) * 2007-06-25 2009-01-08 Nec Tokin Corp 無線ネットワークシステムおよび無線ネットワーク通信方法

Also Published As

Publication number Publication date
JP2010268803A (ja) 2010-12-02
WO2005030039A3 (en) 2005-07-21
CA2539434A1 (en) 2005-04-07
JP2007506433A (ja) 2007-03-22
AU2004275828B2 (en) 2010-04-29
EP1842920B2 (en) 2017-06-21
US20110124000A1 (en) 2011-05-26
EP1842920B1 (en) 2010-01-13
US20070190614A1 (en) 2007-08-16
CA2539434C (en) 2014-03-18
US7858318B2 (en) 2010-12-28
US20090215045A1 (en) 2009-08-27
US20090215061A1 (en) 2009-08-27
US7687233B2 (en) 2010-03-30
JP2015180205A (ja) 2015-10-15
EP2380985A1 (en) 2011-10-26
DK1842920T3 (da) 2010-05-03
ES2339710T5 (es) 2017-10-05
US7524665B2 (en) 2009-04-28
WO2005030039A2 (en) 2005-04-07
AU2004275828A1 (en) 2005-04-07
ES2453895T3 (es) 2014-04-08
US20070009950A1 (en) 2007-01-11
ES2339710T3 (es) 2010-05-24
DE602004025157D1 (de) 2010-03-04
DK2380985T3 (en) 2014-03-17
EP1842920A1 (en) 2007-10-10
PT2380985E (pt) 2014-03-26
EP1670947A4 (en) 2008-11-05
EP1670947B1 (en) 2015-04-01
DK1842920T4 (da) 2017-08-21
US8097410B2 (en) 2012-01-17
JP5840539B2 (ja) 2016-01-06
US7482141B2 (en) 2009-01-27
JP5094920B2 (ja) 2012-12-12
EP2380985B1 (en) 2014-01-01
EP2336360A1 (en) 2011-06-22
US8426128B2 (en) 2013-04-23
JP2012161315A (ja) 2012-08-30
US20060240440A1 (en) 2006-10-26
AU2010203318A1 (en) 2010-08-12
AU2010203318B2 (en) 2012-07-12
EP1670947A2 (en) 2006-06-21
PL1842920T5 (pl) 2018-04-30
ATE455174T1 (de) 2010-01-15
PL1842920T3 (pl) 2010-06-30

Similar Documents

Publication Publication Date Title
HK1093223A1 (en) Methods and compositions for the correlation of single nucleotide polymorphisms in the vitamin epoxide reductase gene and warfarin dosage
TW200636075A (en) Detection of nucleic acid variation by cleavage-amplification method
WO2004058990A3 (en) Genetic polymorphisms associated with stenosis, methods of detection and uses thereof
WO2004013357A3 (en) Nucleotide sequences specific to francisella tularensis and methods for the detection of francisella tularensis
HK1098792A1 (en) Base specific cleavage of methylation-specific amplification products in combination with mass analysis
ATE330038T1 (de) Nukleinsäure-biosensor
WO2008034110A3 (en) Use of taq polymerase mutant enzymes for dna amplification in the presence of pcr inhibitors
AU2003226052A8 (en) Methods for detecting abnormally methylated nucleic acid in heterogeneous biological samples
AU2003241311A1 (en) Simple catalytic dna biosensors for ions based on color changes
WO2005073722A3 (en) Luminogenic and nonluminogenic multiplex assay
AU2002232177A1 (en) Method of detecting nucleotide polymorphism
WO2003054166A3 (en) Nucleotide polymorphisms associated with osteoarthritis
WO2003087763A3 (en) Association of polymorphisms in the sost gene region with bone mineral density
WO2006044686A3 (en) Methods and compositions for predicting drug responses
EP1741793A4 (en) HYBRIDIZATION PROCESS
WO2005026389A3 (en) Ligation-based method of analysis of single nucleotide polymorphisms on genomic dna
EP1514946A4 (en) METHOD FOR DETECTING GENE POLYMORPHISM
WO2004000995A3 (en) Methods, probes, and accessory molecules for detecting single nucleotide polymorphisms
WO2004009843A3 (de) Nachweis von mikroorganismen
WO2004099755A3 (en) Method of electrochemical detection of somatic cell mutations
WO2006065971A3 (en) Compositions and methods for polynucleotide amplification and detection
WO2002079512A3 (en) Method for detection and quantification of the fungus aspergillus fumigatus using quantitative pcr
EP1650300A4 (en) METHOD FOR ASSESSING THE RISK OF DRUG-INDUCED GRANULOCYTOPENIA
WO2002079513A3 (en) Method for the detection and quantification of the fungus stachybotrys chartarum using quantitative pcr
WO2005003388A3 (en) Fluorescence assays for nucleic acid polymerase activity

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20200921